Brief: Orexo Expects Reduced Opex In H2 Compared To H1

Orexo AB

18/07/2023 07:07

July 18 (Reuters) - Orexo AB  ORX.ST :
    * FINANCIAL OUTLOOK 2023: BUPRENORPHINE/NALOXONE MARKET WILL
GROW
4-7 PERCENT, BASED ON CURRENT GROWTH TRAJECTORY
    * FINANCIAL OUTLOOK 2023: GROUP REVENUES WILL INCREASE, WITH
ZUBSOLV US REVENUES IN LINE WITH 2022
    * FINANCIAL OUTLOOK: REDUCED OPEX IN H2 COMPARED TO H1
    * FINANCIAL OUTLOOK: EBITDA IN BALANCE IN H2

Source text for Eikon:  ID:nWkr4TX6zg 
Further company coverage:  ORX.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))